# CellCarta and Imagene AI expand AI biomarker collaboration for pharma

Digest AI · Research · published 2026-10-01T13:46:01Z

Canonical: https://digestai.news/story/cellcarta-and-imagene-ai-expand-ai-biomarker-collaboration-for-pharma

## Summary

CellCarta and Imagene AI announced a deeper partnership on October 1, 2026, to help biopharma firms develop and scale AI-powered biomarkers and companion diagnostics. The collaboration merges Imagene AI’s AI-driven assay development and biomarker prediction tools with CellCarta’s global lab infrastructure, clinical trial support, and regulatory expertise. Work is already underway with two unnamed global pharmaceutical companies, including an AI-powered immunohistochemistry (IHC) program and a project using Imagene AI’s Lung Prediction Panel for non-small cell lung cancer (NSCLC). The panel analyzes H&E whole-slide images to predict biomarkers in minutes, though it is designated for Research Use Only (RUO) and not for clinical diagnostics.

The partnership builds on Imagene AI’s membership in CellCarta’s Digital Pathology and AI Consortium, launched in July 2026. The consortium aims to accelerate biomarker discovery, patient stratification, and clinical trial execution across oncology and other diseases. CellCarta’s Chief Medical Officer, Ehab A. El-Gabry, emphasized the shift toward quantitative, reproducible AI-driven diagnostics. Both companies will showcase the collaboration at the World CB and CDx Summit in Boston from October 5–8, 2026.

## Key points

- CellCarta and Imagene AI partner to combine AI biomarker tools with global lab and regulatory support for pharma
- Two undisclosed global pharma programs underway: IHC diagnostics and NSCLC biomarker prediction via H&E images
- Imagene AI’s Lung Prediction Panel analyzes slides in minutes but remains RUO, not for clinical use

## Why it matters

This collaboration bridges AI-driven biomarker discovery with clinical trial and regulatory readiness, potentially speeding up drug development for pharma. The integration of AI pathology with lab infrastructure could reduce time-to-market for diagnostics, though RUO status limits immediate clinical impact.

## Sources

1. [CellCarta, Imagene AI Broaden Ties on AI Biomarkers, Companion Diagnostics](https://unite.ai/cellcarta-imagene-ai-broaden-ties-on-ai-biomarkers-companion-diagnostics) (Unite.AI, 2026-10-01)

## Cite

Digest AI, "CellCarta and Imagene AI expand AI biomarker collaboration for pharma", 1 October 2026, https://digestai.news/story/cellcarta-and-imagene-ai-expand-ai-biomarker-collaboration-for-pharma

---

Written by Digest AI's editorial model from the linked sources; the sources are the record. Headlines, digests and key points are written by Digest AI and may be quoted with a link to the story page. Linked articles belong to their publishers. Terms: https://digestai.news/terms#reuse
JSON: https://digestai.news/story/cellcarta-and-imagene-ai-expand-ai-biomarker-collaboration-for-pharma.json